BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/29/2024 6:31:20 AM | Browse: 371 | Download: 942
Publication Name World Journal of Experimental Medicine
Manuscript ID 98525
Country Grenada
ISSN 2220-315x (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment
Manuscript Source Invited Manuscript
All Author List Kevan J English
ORCID
Author(s) ORCID Number
Kevan J English http://orcid.org/0009-0006-8893-5696
Funding Agency and Grant Number
Corresponding Author Kevan J English, MD, Doctor, Doctor, Research Scientist, Department of Medicine, Division of Gastroenterology & Hepatology, Saint George’s University School of Medicine, University Centre, Saint George 33334, Saint George, Grenada. kenglish@sgu.edu
Key Words Anal cancer; Squamous cell carcinoma; Chemoradiation therapy; Human papillomavirus; Immunosuppression
Core Tip Anal cancer is a rare malignancy, comprising 1%-6% of anorectal tumors. The incidence of anal carcinoma has been steadily increasing worldwide, and diagnosis is often challenging due to the similarities in clinical presentation to benign rectal diseases such as hemorrhoids. Roughly 85% of anal cancers are squamous cell carcinoma, and human papillomavirus infection and immunosuppression are major risk factors for the disease. Chemoradiation is the treatment of choice for early-stage cancer, while systemic therapy is used for metastatic disease. Novel cytotoxic agents in combination with immunotherapy have produced favorable outcomes in patients with advanced disease.
Publish Date 2024-08-29 06:31
Citation

English KJ. Anal carcinoma - exploring the epidemiology, risk factors, pathophysiology, diagnosis, and treatment. World J Exp Med 2024; 14(3): 98525

URL https://www.wjgnet.com/2220-315x/full/v14/i3/98525.htm
DOI https://dx.doi.org/10.5493/wjem.v14.i3.98525
Full Article (PDF) WJEM-14-98525-with-cover.pdf